Abbott Header Logo
Logo Image

ALINITY m CMV ASSAYS

ALINITY m CMV WB ASSAY (WHOLE BLOOD)
ALINITY m CMV ASSAY (PLASMA)

 

For In Vitro Diagnostic Use.

ALINITY m CMV ASSAY image
ALINITY m CMV ASSAY image
ALINITY m CMV ASSAY image

ABBOTT'S HIGH PERFORMING TESTING AT DECISIVE MOMENTS IN TRANSPLANT PATIENT CARE

 

 

CMV testing on the Alinity m system delivers accurate and timely viral load results, which helps clinicians guide patient care with confidence.

 

Instructions For Use
VIEW ORDERING INFORMATION
Improved Operational Efficiency
  • Alinity m is a continuous and random-access molecular analyzer with a time to first result of less than ~ 115 minutes that provides the ability to eliminate batching procedures and lead to improved laboratory workflow
  • Random access and STAT prioritization provide timely results that support clinicians in their decision to initiate and manage treatment effectively
Improved Confidence
  • Dual-target assay design helps provides robust, accurate and sensitive detection of Cytomegalovirus (CMV) from plasma or whole blood sample types
  • Assay is standardized to the 1st World Health Organization (WHO) International Standard for Human Cytomegalovirus for Nucleic Acid Amplification Techniques (NIBSC Code: 09/162)
  • Alinity m provides the ability to test Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV) from a single plasma or whole blood sample, which is critical for transplant patients who are at risk of developing coinfections

CMV (Plasma)

The Alinity m CMV assay is an in vitro polymerase chain reaction (PCR) assay for use with the automated Alinity m System to detect and quantitate cytomegalovirus (CMV) DNA in human plasma. The Alinity m CMV assay is intended for use as an aid in the diagnosis and management of CMV in transplant patients and other immunocompromised patients. The assay is intended for use in conjunction with clinical presentation and other laboratory markers as an indicator of initiation of therapy and for use as an aid in monitoring viral response to antiviral treatment as measured by changes in CMV DNA levels in plasma. This assay is not intended to be used in screening blood, blood products, tissue or organ donors for CMV.

Limitations

  • Optimal performance of this test requires appropriate specimen collection and handling (refer to the SPECIMEN COLLECTION AND PREPARATION FOR ANALYSIS section of the package insert).
  • Human plasma (K2 EDTA, K3 EDTA, and PPT) specimens may be used with the Alinity m CMV assay. The use of other plasma tubes have not been evaluated.
  • Debris within plasma specimens (eg, fibrin strands) may interfere with sample processing.
  • The instruments and assay procedures reduce the risk of contamination by amplification product. However, nucleic acid contamination from the calibrators, positive controls, or specimens must be controlled by good laboratory practice and careful adherence to the procedures specified in the package insert.
  • If the CMV results are inconsistent with clinical evidence, additional testing is suggested to confirm the result.
  • A specimen with a result of “Not Detected” cannot be presumed to be negative for CMV DNA.
  • When serially monitoring the CMV viral load in patients, 1 specimen type should be used throughout the monitoring period. Follow institutional/society guidelines as appropriate.
  • Due to inherent differences between technologies, it is recommended that, prior to switching from one technology to the next, users perform method correlation studies in their laboratory to qualify technology differences. Users should follow their own specific policies/procedures.

CMV Whole Blood

The Alinity m CMV WB assay is an in vitro polymerase chain reaction (PCR) assay for use with the automated Alinity m System to detect and quantitate cytomegalovirus (CMV) DNA in human whole blood.

The Alinity m CMV WB assay is intended for use as an aid in the diagnosis and management of CMV in transplant patients and other immunocompromised patients. The assay is intended for use in conjunction with clinical presentation and other laboratory markers as an indicator of initiation of therapy and for use as an aid in monitoring viral response to antiviral treatment as measured by changes in CMV DNA levels in whole blood. This assay is not intended to be used in screening blood, blood products, tissue or organ donors for CMV.

Limitations

  • Optimal performance of this test requires appropriate specimen collection and handling (refer to the SPECIMEN COLLECTION AND PREPARATION FOR ANALYSIS section of the package insert).
  • Human whole blood (K2 EDTA or K3 EDTA) specimens may be used with the Alinity m CMV WB assay. The use of other specimen types or collection tubes has not been evaluated.
  • The instruments and assay procedures reduce the risk of contamination by amplification product. However, nucleic acid contamination from the calibrators, positive controls, or specimens must be controlled by good laboratory practice and careful adherence to the procedures specified in the package insert.
  • If the CMV results are inconsistent with clinical evidence, additional testing is suggested to confirm the result.
  • A specimen with a result of “Not Detected” cannot be presumed to be negative for CMV.
  • When serially monitoring the CMV viral load in patients, 1 specimen type should be used throughout the monitoring period. Follow institutional/society guidelines as appropriate. 
  • Due to inherent differences between technologies, it is recommended that, prior to switching from one technology to the next, users perform method correlation studies in their laboratory to qualify technology differences. Users should follow their own specific policies/procedures.

The Alinity m CMV WB AMP Kit is an in vitro diagnostic device which is CE-marked. Notified body number 2797.

Assay

Alinity m CMV and Alinity m CMV WB

Technology

Real-time PCR

Assay Run Time

< ~115 min time to first result

Throughput

300 samples in ~8 hours

Probe Design

Single-stranded probe design

Target Regions

UL34 and UL80.5

Results Units

IU/mL or Log (IU/mL)

Standardization

1st World Health Organization (WHO) International Standard for Human Cytomegalovirus for Nucleic Acid Amplification Techniques (NIBSC code: 09/162)

Internal Control

Yes

External Controls

Negative, Low Positive, High Positive

Calibrators

2 calibrator levels (single-use tubes)

Plasma Sample Types (09N46-090)

Plasma K2 EDTA; K3 EDTA; Plasma Preparation Tubes (PPTs)

Plasma Input Volume (Aspirated)

500 µL

Plasma Limit of Detection (LOD)

LoD = 30 IU/mL
Probit analysis of the data determined that the concentration of CMV DNA in plasma detected with 95% probability was 18.98 IU/mL(95% CI: 11.16 to 62.82 IU/mL)

Plasma Linear Range

1.48 Log IU/mL to 8.00 Log IU/mL

Plasma Precision

≤ 0.25 Log IU/mL Standard Deviation from 2.70 to 8.00 Log IU/mL; ≤ 0.50 Log IU/mL Standard Deviation from 1.70 Log IU/mL to < 2.70 Log IU/mL.​

Whole blood Sample Types (09N43-092)

Whole blood K2 EDTA; K3 EDTA

Whole blood Input Volume (Aspirated)

500 µL

Whole blood Limit of Detection (LOD)

100 IU/mL (2.00 Log IU/mL)

Whole blood Linear Range

2.00 Log IU/mL to 8.00 Log IU/mL

Whole blood Precision

≤0.25 Log IU/mL from 3.00 to 8.00 Log IU/mL; ≤0.50 Log IU/mL from 2.00 Log IU/mL to <3.00 Log IU/mL

ALINITY M CMV

ORDERING INFO

REQUEST INFO
ALINITY M CMV WB (WHOLE BLOOD)

ORDERING INFO

REQUEST INFO
Explore

Discover a broad menu and robust assay design to deliver operational efficiency and reliable results. 

View Product Information

Learn more about the Alinity m BKV assay, discover resources and view ordering information. 

View ALINITY m BKV Assay

Learn how the Alinity m Resp-4-Plex assay offers workflow efficiency and high throughput solutions.

View Resp-4-plex assay
Logo Image

© 2024 Abbott, Abbott Park, Illinois, U.S.A.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. Other trademarks are the property of their respective owners.

This Internet site that you have requested is intended for the residents of a particular country or countries and may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions. If you are a resident of a country other than those to which this site is directed, contact your local Abbott affiliate to obtain the appropriate product information for your country of residence.

YOU ARE ABOUT TO ENTER AN ABBOTT COUNTRY OR REGION SPECIFIC WEBSITE.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.

DO YOU WISH TO CONTINUE AND ENTER THIS WEBSITE?

YOU ARE ABOUT TO ENTER AN ABBOTT COUNTRY OR REGION SPECIFIC WEBSITE.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.

DO YOU WISH TO CONTINUE AND ENTER THIS WEBSITE?